Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults ≥65 Years of Age

NCT01172054 is registered in ClinicalTrials.gov with VaxInnate Corporation as lead sponsor.

NCT NCT01172054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01172054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults ≥65 Years of Age
Lead sponsor
VaxInnate Corporation
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
November 30, 2011
Enrollment
292 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza